Alchemab Therapeutics
Amparo Toboso Navasa is a seasoned bioinformatician with extensive experience in antibody discovery and drug discovery. Currently serving as a Senior Bioinformatician at Alchemab Therapeutics Ltd since October 2021, Amparo has led the development of a platform for integrating target information to support pipeline decisions. Prior experience includes a role as Senior Scientist at BenevolentAI, where Amparo managed multidisciplinary teams in drug discovery programs, resulting in a patent and a co-authored paper. Amparo's academic background includes a PhD in Immunology and Cancer from UCL, alongside multiple master's degrees in Bioinformatics, Molecular Biomedicine, and Biotechnology. Amparo has contributed to significant research at institutions including The Francis Crick Institute and Cancer Research UK.
Alchemab Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.